Update: now available from three manufacturers.
Teva Pharmaceuticals, Alembic Pharmaceuticals, and Glenmark Pharmaceuticals have all announced the U.S. launch of generic VESIcare (solifenacin succinate) tablets.
Initially approved for Astellas in 2004, solifenacin succinate is indicated for those suffering from overactive bladder with additional symptoms of urge urinary incontinence, urgency, and urinary frequency, the generic will follow the brand name dosages of 5 mg and 10 mg tablets.
Starting dosage is 5 mg and may only be increased to 10 mg after the patient exhibits signs that they can tolerate the drug.
Trending: Common Food Additive May Impair Immune Response to Flu Vaccine
5 mg is the limiting dosage for patients with severe renal impairment, moderate hepatic impairment, or are concomitantly using potent CYP3A4 inhibitors. Solifenacin succinate is not recommended, but not contraindicated, for patients with severe hepatic impairment.
Solifenacin succinate is contraindicated for patients suffering from urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and those that demonstrate a hypersensitivity to the drug.
Full solifenacin succinate prescribing information can be accessed here.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
March 20th 2024Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.